Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
SAN CLEMENTE, Calif., June 01, 2017 -- David Steenblock, an osteopathic physician based in San Clemente, CA, is uniquely qualified to address toxicity in the human body through his use of EDTA Chelation Therapy.
Dr. Steenblock uses EDTA (EthyleneDiamineTetraAcetic Acid) Chelation Therapy, a procedure that removes heavy metals from the blood, and consistently improves blood flow and relieves symptoms associated with atherosclerosis in over 80% of patients treated.
“It’s been observed that patients being treated for acute lead intoxification with EDTA with cardiovascular disease, showed improved stress tolerance and less chest pain with physical exertion, “ said Dr. Steenblock.
Dr. Steenblock believes that the benefits of EDTA chelation can improve circulation; reduce cholesterol levels, decrease high blood pressure; and lower insulin requirements in diabetics.
In addition, Dr. Steenblock uses EDTA Chelation Therapy with a combination of hyperbaric oxygen therapy, leading to significant neurologic improvements for stroke patients.
Dr. David Steenblock is a leading-edge physician in many fields of medicine, from stroke care, to acute brain trauma, to generative and cell-based medicine in the treatment of ALS, Cerebral Palsy and other chronic and degenerative diseases. For more information about Dr. Steenblock’s work in stem cell therapies, visit www.stemcellmd.org.
CONTACT: Irene Doti [email protected]
